Long-term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders

Current Alzheimer Research

Volumn 6, Issue 2, 2009, Pages 144-151

  Vellas, Bruno ^a   Black, R ^b   Thal, Leon J ^c   Fox, Nick C ^d   Daniels, M ^e   McLennan, G ^e   Tompkins, C ^e   Leibman, C ^e   Pomfret, M ^b   Grundman, Michael ^e  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ELAN PHARMACEUTICALS   (United States)

Author keywords

A ; Alzheimer's disease; Amyloid; Immunotherapy; NTB

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRAIN SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; ENCEPHALITIS; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; COGNITION; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 64549152492     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509787602852     Document Type: Article

References (19)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimer Dement 3: 186-191 (2007).
2. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-p attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400: 173-177 (1999).
3. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F p-amyloid precursor protein. Nature 373: 523-527 (1995).
4. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey G, Hardy J, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985 (2000).
5. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schimdt SD, et al. Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982 (2000).
6. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8: 1263-1269 (2002).
7. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64: 94101 (2005).
8. Orgogozo J-M, Gilman S, Dartigues J-F, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61: 46-54 (2003).
9. Gilman S, Killer M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1563-1572 (2005).
10. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer's disease. Neurology 64: 1553-1562 (2005).
11. Ferrer I, Boada RM, Sanchez Guerra ML, Rossor MN, Griffith SG, Jenkins L, et al. Neuropathology and pathogenesis of encephalitis following amyloid-p immunization in Alzheimer's disease. Brain Pathol 14: 11-20 (2004).
12. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer's disease. Neurology 64: 129-131 (2005).
13. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H and Weller RO. Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report. Nat Med 9: 448-452 (2003).
14. Gauthier S, Gelinas I and Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr 9(suppl 1): 163-165 (1997).
15. Stern Y, Albert SM, Sano M, Jacobs DM, Tang MX, Marder K, et al. Assessing patient dependence in Alzheimer's disease. J Gerontol 49: M216-222 (1994).
16. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 2412-2414 (1993).
17. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M and Grundman M. A neuropsychological test battery for use in Alzheimer's disease clinical trials. Arch Neurol 64: 1323-1329 (2007).
18. Folstein MF, Folstein SE and McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198 (1975).
19. Rosen WG, Mohs RC and Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364 (1984).